The Trump administration plans to end a Medicare Part D subsidy program in 2027 that currently helps low-income beneficiaries afford prescription drugs, according to ABC News. The program's elimination would represent a significant change to how Medicare covers drug costs for millions of Americans.
Medicare Part D is the federal prescription drug benefit program. The subsidy in question, often referred to as the low-income subsidy or Extra Help, is designed to reduce out-of-pocket drug costs for Medicare enrollees who meet income and asset requirements. Beneficiaries who qualify receive assistance with premiums, deductibles, and copayments.
The administration's decision to wind down the program is set to take effect in 2027. Details about what, if anything, would replace the subsidy were not specified in the report. The announcement came as the administration has been working to reshape several federal health programs.
The program currently serves a large number of Medicare beneficiaries. Eliminating it would shift more drug costs directly onto lower-income enrollees, many of whom are elderly or have disabilities. Prescription drug affordability has been a persistent concern for this population, and the subsidy has been credited with helping people stay on medications they would otherwise struggle to afford.
Health policy advocates and lawmakers have frequently pointed to the low-income subsidy as one of the more effective tools within Medicare for addressing drug cost burdens. The program's end would arrive in the same period when other changes to Medicare drug pricing, including provisions from recent federal legislation, are also taking effect.
The timeline gives affected beneficiaries and policymakers roughly a year to respond before the program concludes.
